Sino Biological,Inc.

Equities

301047

CNE100004Q23

Biotechnology & Medical Research

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
70.95 ^CNY	+1.57%		+4.96%	-13.90%

Apr. 24	Sino Biological,Inc. Proposes Final Cash Dividend for the Year 2023	CI
Apr. 23	Sino Biological,Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Bio-Link Pharmaceutical Technology Co., Ltd. announced that it has received funding from Cathay Capital Private Equity SAS, Sino Biological,Inc., Suzhou GSL Venture Capital Management Company, Beijing GSR United Capital Management Consulting Co., Ltd., Tianjin Qianxi Investment Management Partnership Ent. (L.P.), Shanghai Pudong Haiwang Private Fund Management Co., Ltd. and other investors

February 20, 2024

Bio-Link Pharmaceutical Technology (Shanghai) Co., Ltd. announced that it has raised hundreds of millions of yuan in a round of funding on February 21, 2024. The transaction included participation from new investors Shanghai Pudong Haiwang Private Fund Management Co., Ltd.,Yuanxi Haihe (Tianjin) Biomedical Industry Fund Partnership Ent. (L.P.),a fund managed by Suzhou GSL Venture Capital Management Company,Beijing GSR United Capital Management Consulting Co., Ltd. and Tianjin Qianxi Investment Management Partnership Ent.

(L.P.),Tianjin Haihe Kailaiying Biomedical Industry Innovation Investment Fund (Limited Partnership,Bridge Hill Capital,Bloomage Healthcare Consumer Goods Industry Fund,Xincheng (Beijing) Private Equity Fund Management Co., Ltd.,Huaxi Healthcare Consumer Goods Industry Fund, returning investors Cathay Capital Private Equity SAS,Xincheng Fund and Sino Biological,Inc.

Latest news about Sino Biological,Inc.

Sino Biological,Inc. Proposes Final Cash Dividend for the Year 2023	Apr. 23	CI
Sino Biological,Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 23	CI
Tranche Update on Sino Biological,Inc.'s Equity Buyback Plan announced on February 23, 2024.	Apr. 02	CI
Sino Biological,Inc. commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on February 19, 2024.	Feb. 22	CI
Bio-Link Pharmaceutical Technology Co., Ltd. announced that it has received funding from Cathay Capital Private Equity SAS, Sino Biological,Inc., Suzhou GSL Venture Capital Management Company, Beijing GSR United Capital Management Consulting Co., Ltd., Tianjin Qianxi Investment Management Partnership Ent. (L.P.), Shanghai Pudong Haiwang Private Fund Management Co., Ltd. and other investors	Feb. 20	CI
Sino Biological,Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-24	CI
Sino Biological to Acquire Canada’s SignalChem Biotech for $48 Million	23-10-23	MT
Sino Biological,Inc. entered into Share Purchase Agreement to acquire SignalChem Biotech Inc. from Signalchem Lifesciences Corporation for CAD 65.85 ?million.	23-10-19	CI
Sino Biological,Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-27	CI
Certain A Shares of Sino Biological Inc. are subject to a Lock-Up Agreement Ending on 17-AUG-2023.	23-08-16	CI
Sino Biological Unit to Lease Beijing Property to Shenzhou Cell Engineering	23-05-26	MT
Sino Biological Buys Land for 918 Million Yuan	23-05-23	MT
Sino Biological,Inc Approves the Final Cash Dividend for the Year 2022, Payable on 24 May 2023	23-05-16	CI
Sino Biological,Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
Sino Biological,Inc. Proposes Final Cash Dividend for the Year 2022	23-04-24	CI
Sino Biological,Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-21	CI
Sino Biological,Inc. Approves Board Elections	23-03-23	CI
PhaBuilder announced that it has received $53.4 million in funding from Sino Biological,Inc., Beijing Zhonghai Investment Management Co., Ltd., Shanghai Free Trade Zone Equity Fund Management Co., Ltd., Chengtong Fund Management Co., Ltd., CNPC Kunlun Capital Co., Ltd., Shanghai Lingang Innovation Center Co., Ltd.	23-02-01	CI
Sino Biological to Form 1 Billion Yuan Industrial Investment Fund	22-12-20	MT
Investors bet China's rally on easing COVID curbs will be furious but fleeting	22-12-05	RE
ChiNext Announces Construction of Its New Us-Based Center for Bioprocessing	22-11-21	CI
PhaBuilder announced that it expects to receive CNY 95 million in funding from Sino Biological,Inc., Lhasa Ailike Investment Consulting Co., Ltd	22-11-02	CI
Sino Biological,Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-25	CI
Sino Biological,Inc.(XSEC:301047) added to S&P Global BMI Index	22-09-19	CI
Certain A Shares of Sino Biological Inc. are subject to a Lock-Up Agreement Ending on 17-AUG-2022.	22-08-16	CI

Chart Sino Biological,Inc.

Duration

Period

More charts

Company Profile

Sino Biological Inc is a China-based biotechnology company engaged in the research and development, production, sales and technical services of biological reagents. The Company's main business includes products such as recombinant proteins, antibodies, genes and culture media, as well as the development of recombinant proteins and antibodies, and biological analysis and testing services. The Company operates in the domestic market and overseas markets.

Sector

Biotechnology & Medical Research

Calendar

2024-04-28 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Sino Biological,Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

70.95 CNY

Average target price

102.5 CNY

Spread / Average Target

+44.47%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SINO BIOLOGICAL,INC.	-13.90%	1.27B
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research